CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Cyclophosphamide, Liposome doxorubicin and
Dexamethasone（CDD) Plus Bortezomib might have effective in extramedullary plasmacytoma.